What if there was a natural GLP-1 alternative that actually helped with weight loss?

What was studied

A randomized, double-blind, crossover clinical trial at the University of Auckland and Plant & Food Research New Zealand. Nineteen healthy-weight men received either 500mg of Amarasate hops extract (delivered to the stomach or duodenum) or placebo on three occasions with one-week washouts. After each dose, researchers measured blood levels of GLP-1, CCK, PYY, and ghrelin, and recorded food intake at a standardized lunch.

Key Findings

• Both gastric and duodenal hops delivery significantly increased GLP-1, CCK, and PYY - the three primary satiety hormones
• Participants ate significantly less at the ad libitum test meal versus placebo
• Effect attributed to bitter taste receptors (TAS2Rs) on gut enteroendocrine cells
• Notably: subjective hunger ratings didn't change much - yet participants still ate less. A "bitter brake" mechanism operating below conscious appetite

What was studied

Researchers at the University of Illinois tested 27 different flavonoids and phenolic compounds - the kind found in berries, citrus, and grapes - for their ability to inhibit DPP-4, the enzyme that breaks down GLP-1 within minutes of secretion. Each compound was measured both in laboratory enzyme assays and through computational docking analysis.

Key Findings

• Luteolin showed an IC50 of 0.12 μM - in the top tier of natural DPP-4 inhibitors tested
• 35× more potent than diprotin A, the pharmaceutical reference compound (IC50 4.21 μM)
• Computational modeling confirmed luteolin docks into the S2 and S3 active pockets of DPP-4
• Inhibition is non-competitive - luteolin keeps working regardless of how much GLP-1 is being produced

What was studied

A Taiwanese team used a multi-stage discovery pipeline: molecular docking to screen phenolic compounds for DPP-4 binding affinity, in vitro enzymatic assays to confirm inhibition, cell culture studies in intestinal, muscle, and pancreatic cells, and finally in vivo testing in diet-induced diabetic mice to confirm long-term safety and efficacy.

Key Findings

• Multiple natural phenolic compounds bind directly to DPP-4 with measurable inhibitory activity
• Curcumin and resveratrol both demonstrated strong inhibition in enzymatic tests
• Diabetic mice showed reduced blood glucose and long-term HbA1c regulation with phenolic supplementation
• Confirms the class effect: natural polyphenols - DHM, EGCG, curcumin, resveratrol - genuinely inhibit DPP-4

What was studied

A prospective, randomized, double-blind, placebo-controlled trial at the University of Mississippi Medical Center. Eighty adults with elevated cholesterol were randomized to one of four arms: 125mg pterostilbene twice daily, 50mg twice daily, 50mg plus grape extract 100mg twice daily, or placebo - for 6-8 weeks. Researchers tracked lipids, blood pressure, body weight, and safety markers.

Key Findings

• Significant systolic blood pressure reduction (-7.8 mmHg) at the high dose
• Significant diastolic blood pressure reduction (-7.3 mmHg)
• Minor but measurable weight loss in non-medicated patients (-0.62 kg/m² BMI)
• No adverse drug reactions on hepatic, renal, or glucose markers across any arm
• 91.3% completion rate - well-tolerated at all doses

What was studied

A landmark randomized clinical trial investigating whether oral 5-hydroxytryptophan (5-HTP) — the immediate biochemical precursor to serotonin — could influence appetite, food intake, and body weight in subjects with elevated BMI. Over multiple weeks, participants received either 5-HTP or placebo, with food intake tracked across standardized meals.

Key Findings

• Significant reduction in carbohydrate intake in the 5-HTP group versus placebo
• Earlier onset of satiety reported during meals
• Measurable weight reduction in 5-HTP group across the treatment period
• 5-HTP crosses the blood-brain barrier — the body converts it to serotonin in the brain
• Effects attributed to enhanced serotonergic signaling in hypothalamic satiety centers

What was studied

Researchers at Cedars-Sinai combined four methods: immunohistochemistry on human ileum tissue to locate the bitter taste receptor TAS2R38, virtual screening of ~2.5 million compounds for TAS2R38 binding affinity, in vitro testing of top hits in HuTu-80 cells (with TAS2R38 knockout controls), and in vivo animal studies. The hypothesis: bitter receptors in the gut could be activated to trigger GLP-1 release without entering the bloodstream.

Key Findings

• TAS2R38 receptors were confirmed co-localized with GLP-1 in human L-cells of the ileum
• TAS2R38 agonists stimulated GLP-1 release dose-dependently in cell cultures
• Knockout studies showed dramatically reduced GLP-1 response without TAS2R38 - confirming the receptor's role
• In vivo studies confirmed gut-local activation works without systemic absorption

What was studied

A foundational pharmacokinetic study testing whether piperine - the active alkaloid in black pepper, known to inhibit hepatic and intestinal glucuronidation - could enhance curcumin's notoriously poor oral bioavailability. Researchers measured serum curcumin concentrations at multiple time points after dosing, in both rats and healthy human volunteers.

Key Findings

• Curcumin alone has extremely poor oral bioavailability - most is metabolized before reaching circulation
• Piperine blocks the enzymes responsible for curcumin's rapid breakdown
• Combined dosing produced a 2,000% increase in curcumin bioavailability in human volunteers
• Peak curcumin concentration arrives ~45 minutes after co-administration with piperine
• No adverse effects observed at the studied dosages

What was studied

Researchers investigated multiple commercially-available plant preparations for their capacity to elicit thermogenesis — the body’s heat production from metabolizing food — in healthy human subjects. Yerba mate was studied alongside other herbal extracts for its bioactive compound profile and metabolic effects.

Key Findings

• Yerba mate produced significant increase in resting energy expenditure versus placebo
• Thermogenic effect was sustained for several hours post-ingestion
• Mechanism involves synergy of caffeine, theobromine, theophylline, and chlorogenic acids
• Effect was distinct from simple caffeine stimulation — broader metabolic engagement
• Sustained metabolic rate elevation without the crash profile of caffeine alone

What was studied

A 60-day prospective, randomized, double-blind, placebo-controlled trial conducted at Asha Hospital in Hyderabad. Sixty-four adults with a history of chronic stress were randomized to receive either 300mg of KSM-66 ashwagandha twice daily (600mg total) or matching placebo. Researchers tracked serum cortisol, the Perceived Stress Scale (PSS), the Depression-Anxiety-Stress Scale (DASS), and General Health Questionnaire scores at baseline and at the end of the study.

Key Findings

• Serum cortisol reduced 27.9% in the ashwagandha group versus placebo
• Perceived Stress Scale (PSS) scores reduced 44% versus placebo
• Significant improvements across all four subscales of the General Health Questionnaire
• Significant reductions in depression, anxiety, and stress markers (DASS)
• Excellent safety profile - no significant adverse events reported
• Established KSM-66 as the standardized full-spectrum extract with the strongest cortisol-reduction evidence